Our mission is to develop and deliver innovative therapies that improve the lives of those affected by cancer. Led by a team with a deep understanding of the biology of cancer and extensive drug discovery, development, and commercialization experience, we are rapidly advancing two novel cancer therapies.
COSELA™ (trilaciclib) is a first-in-class therapy designed to improve outcomes for people with cancer who are treated with chemotherapy. Rintodestrant is a potential best-in-class oral selective estrogen receptor degrader, or SERD, for the treatment of ER+ breast cancer.